Just to add to the contractual fun and talk of export bans etc, a little cameo appearance by the as yet unapproved vaccine from Novavax.
An article appeared yesterday on Reuters citing an anonymous EU source explaining why the EU hasn't yet signed a contract with Novavax. The article suggested Novavax were blaming the contract delay on "legal issues", but suggesting that in reality they were stalling because they had raw material and supply problems.
Unsurprisingly their share price took a tumble and JP Morgan had to release a briefing for them explaining that their main supply issue at the moment is on the finish and fill side - they're struggling to get the sheer number of filters and vials etc needed. Basically an area where their competition is the other vaccine makers, and everyone's waiting for more supplies, with them looking for locations where they are nearer the front of the queue.
Their European vaccine factories are starting to produce bulk product - antigen on multiple sites including the UK, Spain, Czech republic and adjuvant in Sweden. They also think they're on track to produce 150m doses/month globally by the end of Q2 - but I don't know how that's split - I know in the longer term (Q3/Q4) a lot of production, including their production for Covax, will be in India.
They do warn though that their US and European supply chains are interlinked, with ingredients moving in both directions to create the finished product. Meanwhile Novavax say they'll be going to the MHRA for approval first ("because that's where the trial was").
Will vaccine diplomacy win out or will they be the next company to go under the PR nightmare microscope? At any rate, it's really not hard to believe that they might be taking their time over every legal clause in the agreement with the EU particularly anything that sounds like a delivery schedule